Transitioning to commercial scale, the company secured key U.S. supply agreements and advanced Factory 02 planning, targeting the high-growth health and performance protein market. Financials show stable losses amid heavy investment, with strong sustainability positioning and positive customer feedback.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.